Biolocity’s Post

🌟 Who do I contact if I have any questions about Biolocity? 🌟 Email us at biolocity@gatech.edu with any questions. Learn more about Biolocity at https://lnkd.in/eCtxXyx6. #Biolocity #MedicalInnovation #Device #Diagnostic #Therapeutic #DigitalHealth #IP #Commercialization #MedicalTechnology #earlystage

Get ready... medical cost growth is expected to rise to the highest level in 13 years, projected at an 8% year-on-year increase in 2025! Top 3 inflators: Inflationary impact on healthcare providers New prescription drug launches, including GLP-1s Utilization and cost of behavioral health Top 3 deflators: Impact of biosimilars Managing total cost of care Implementation of Generative AI?

Tinnitus Treatment Revolutionized as pnq Health Receives FDA Clearance for Integrated Digital Health Platform pnq Health announced that it has received the FDA Clearance as a Class II, Software as a Medical Device for its groundbreaking digital health platform designed to treat tinnitus, one of the world’s most common yet untreated conditions. Unlike traditional approaches that focus solely on the auditory aspect, pnq Health’s model integrates Signal Monitoring Management with internal medicine consultation support via telemedicine, offering a holistic and effective solution for patients that is administered at home and supported by a national network of telehealth medical experts. For more details please click the link! https://lnkd.in/gDWhzjnD #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

Asieris Pharmaceuticals Highlights the P-III Study Data of APL-1702 for Treating Cervical High-Grade Squamous Intraepithelial Lesions at the 2024 EUROGIN Congress and SGO Annual Meeting #asierispharmaceuticals #apl1702 #cervicalcancer #clinicaltrial #phase3 #safety #efficacy #treatment

The US FDA Updates the PDUFA Date of Bristol Myers Squibb’ BLA of Subcutaneous Opdivo (nivolumab and hyaluronidase) #bms #opdivo #clearcellrenalcellcarcinoma #regulatory #bla #usfda #subcutaneous #intravenous #sc #iv #formulation

Discover the latest insights from Elisabeth Rouits, PharmD, PhD, Global Head Clinical Pharmacology-Pharmacometrics at PharmaLex. This article examines strategies for optimizing drug dosing, reducing side effects, and meeting regulatory standards for targeted therapies. Read more: https://lnkd.in/dpERqv_v #TargetedMedicine #PharmaLex #HealthcareInnovation #PersonalizedTherapies #ClinicalPharmacology #RegulatorySuccess

Discover the latest insights from Elisabeth Rouits, PharmD, PhD, Global Head Clinical Pharmacology-Pharmacometrics at PharmaLex. This article examines strategies for optimizing drug dosing, reducing side effects, and meeting regulatory standards for targeted therapies. Read more: https://lnkd.in/gdTH5RXH #TargetedMedicine #PharmaLex #HealthcareInnovation #PersonalizedTherapies #ClinicalPharmacology #RegulatorySuccess

Discover the latest insights from Elisabeth Rouits, PharmD, PhD, Global Head Clinical Pharmacology-Pharmacometrics at PharmaLex. This article examines strategies for optimizing drug dosing, reducing side effects, and meeting regulatory standards for targeted therapies. Read more: https://lnkd.in/gfByEXtq #TargetedMedicine #PharmaLex #HealthcareInnovation #PersonalizedTherapies #ClinicalPharmacology #RegulatorySuccess

Thoughts on this? >> Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharma #productmarketing #pharmaceutical

Published online: "SUBCUTANEOUS DRUG DELIVERY: ADAPTING TO HIGH-VISCOSITY, LARGE-VOLUME DEMANDS". Read the full ONdrugDelivery article 👉 https://lnkd.in/e-Gtm6jQ "Thomas Fontanellaz, Reto Jost and Andreas Schneider discuss how Ypsomed AG is addressing the growing need for subcutaneous injections that accommodate higher volumes and viscosities, with innovative self-injection devices designed to enhance patient comfort and adherence."